GlassScriptPhysician profile
Jerry Ragnauth
NPI 1154300895
$5,188.80
in general payments reported to CMS, 2019-2025
30 companies · $900 in 2025
The $900 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,563 · 2022: $1,247 · 2023: $628 · 2024: $851 · 2025: $900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,379.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $1,338.75 | 2021-2024 | Senza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $574.61 | 2021-2025 | Relistor |
| Ibsa Pharma INC. | $427.02 | 2021-2025 | Tirosint, Licart, Flector |
| Scilex Pharmaceuticals INC. | $426.66 | 2021-2025 | Ztlido |
| Boston Scientific Corporation | $319.39 | 2021-2025 | Wavewriter Alpha Prime 16 |
| Averitas Pharma INC. | $318.07 | 2024-2025 | Qutenza |
| Abbott Laboratories | $249.50 | 2021-2025 | Proclaim, Eterna |
| Curonix LLC | $241.03 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Grt US Holding, INC. | $217.21 | 2021-2022 | |
| Amgen INC. | $163.54 | 2021-2022 | |
| Globus Medical, INC. | $152.05 | 2025 | Senza, Vyrsa V1 |
| Protega Pharmaceutials INC | $88.09 | 2024-2025 | Roxybond |
| Abbvie INC. | $87.63 | 2021-2025 | |
| Redhill Biopharma INC. | $86.30 | 2021 | |
| Medtronic, INC. | $64.94 | 2022-2023 | Kyphon Express II Kyphopak Tray |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertos Medical, INC. | $64.00 | 2022 | |
| Si-Bone, INC. | $50.40 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $48.14 | 2021 | |
| Almatica Pharma LLC | $38.77 | 2021-2023 | Gralise |
| Radius Health, INC. | $32.80 | 2021 | |
| Merz Pharmaceuticals, LLC | $27.19 | 2025 | Xeomin |
| Bioventus LLC | $25.98 | 2025 | Xcell |
| Biohaven Pharmaceuticals, INC. | $24.79 | 2021 | |
| Nalu Medical, INC. | $21.90 | 2025 | Nalu Neurostimulation System |
| Biodelivery Sciences International, INC. | $21.04 | 2021 | |
| Lilly USA, LLC | $19.56 | 2022 | |
| Convatec INC. | $15.84 | 2025 | |
| Hikma Pharmaceuticals USA | $15.47 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $14.84 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $13.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Ragnauth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.